Identifying modulators of CXC receptors 3 and 4 with tailored selectivity using multi-target docking.

The G protein-coupled receptors of the C-X-C subfamily form a group among the chemokine receptors whose endogenous ligands are peptides with a common Cys-X-Cys motif. The CXC chemokine receptors 3 and 4 (CXCR3, CXCR4), which are investigated in this study, are linked to severe diseases such as cancer, multiple sclerosis, and HIV infections. Of particular interest, this receptor pair potentially forms a target for a polypharmacological drug treatment. Considering known ligands from public databases, such dual binders have not been identified yet. We therefore applied large-scale docking to the structure of CXCR4 and a homology model of CXCR3 with the goal to predict such dual binders, as well as compounds selective for either one of the receptors. Using signaling and biochemical assays, we showed that more than 50% of these predictions were correct in each category, yielding ligands with excellent binding efficiencies. These results highlight that docking is a suitable tool for the identification of ligands with tailored binding profiles to GPCRs, even when using homology models. More importantly, we present novel CXCR3-CXCR4 dual modulators that might pave the road to understanding the mechanisms of polypharmacological inhibition of these receptors.

[1]  Brian K. Shoichet,et al.  Structure-Based Discovery of A2A Adenosine Receptor Ligands , 2010, Journal of medicinal chemistry.

[2]  Dominique Schols,et al.  Inhibition of Human Immunodeficiency Virus Replication by a Dual CCR5/CXCR4 Antagonist , 2004, Journal of Virology.

[3]  Jakob S. Jensen,et al.  Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. , 1999, The Journal of clinical investigation.

[4]  Saskia Nijmeijer,et al.  Virtual Fragment Screening: Discovery of Histamine H3 Receptor Ligands Using Ligand-Based and Protein-Based Molecular Fingerprints , 2012, J. Chem. Inf. Model..

[5]  S. McColl,et al.  Antagonism of the Chemokine Receptors CXCR3 and CXCR4 Reduces the Pathology of Experimental Autoimmune Encephalomyelitis , 2008, Brain pathology.

[6]  T. Kenakin,et al.  G Protein-Coupled Receptor Allosterism and Complexing , 2002, Pharmacological Reviews.

[7]  Michael M. Mysinger,et al.  Structure-based ligand discovery for the protein–protein interface of chemokine receptor CXCR4 , 2012, Proceedings of the National Academy of Sciences.

[8]  Maria F. Sassano,et al.  Automated design of ligands to polypharmacological profiles , 2012, Nature.

[9]  J. Baell,et al.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.

[10]  T. Blundell,et al.  Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.

[11]  H. Seno,et al.  The role of CXCR3 and CXCR4 in colorectal cancer metastasis , 2013, International journal of cancer.

[12]  Peter Kolb,et al.  Docking screens: right for the right reasons? , 2009, Current topics in medicinal chemistry.

[13]  K. Shokat,et al.  Targeting the cancer kinome through polypharmacology , 2010, Nature Reviews Cancer.

[14]  M. Karplus,et al.  CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .

[15]  R. Horuk,et al.  Chemokine receptor antagonists: part 2 , 2009, Expert opinion on therapeutic patents.

[16]  N. Heveker,et al.  Effect of Mutations in the Second Extracellular Loop of CXCR4 on Its Utilization by Human and Feline Immunodeficiency Viruses , 1999, Journal of Virology.

[17]  Avner Schlessinger,et al.  Ligand Discovery from a Dopamine D3 Receptor Homology Model and Crystal Structure , 2011, Nature chemical biology.

[18]  Claudio N. Cavasotto,et al.  Discovery of novel chemotypes to a G-protein-coupled receptor through ligand-steered homology modeling and structure-based virtual screening. , 2008, Journal of medicinal chemistry.

[19]  Michael J. Keiser,et al.  The Chemical Basis of Pharmacology , 2010, Biochemistry.

[20]  Gert Vriend,et al.  Increasing the precision of comparative models with YASARA NOVA—a self‐parameterizing force field , 2002, Proteins.

[21]  Nuska Tschammer,et al.  Boronic acids as probes for investigation of allosteric modulation of the chemokine receptor CXCR3. , 2014, ACS chemical biology.

[22]  T. Schwartz,et al.  The minor binding pocket: a major player in 7TM receptor activation. , 2010, Trends in pharmacological sciences.

[23]  I. Kuntz,et al.  Matching chemistry and shape in molecular docking. , 1993, Protein engineering.

[24]  N. Heveker,et al.  Identification of Residues of CXCR4 Critical for Human Immunodeficiency Virus Coreceptor and Chemokine Receptor Activities* , 2000, The Journal of Biological Chemistry.

[25]  J. Irwin,et al.  Docking and chemoinformatic screens for new ligands and targets. , 2009, Current opinion in biotechnology.

[26]  Arthur J. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[27]  M. Peck,et al.  A Small Molecule Antagonist of Chemokine Receptors CCR1 and CCR3 , 2000, The Journal of Biological Chemistry.

[28]  Ryan G. Coleman,et al.  ZINC: A Free Tool to Discover Chemistry for Biology , 2012, J. Chem. Inf. Model..

[29]  F. Balkwill.  Cancer and the chemokine network , 2004, Nature Reviews Cancer.

[30]  Peter Kolb,et al.  Limits of Ligand Selectivity from Docking to Models: In Silico Screening for A1 Adenosine Receptor Antagonists , 2012, PloS one.

[31]  I. D. de Esch,et al.  Identification of Overlapping but Differential Binding Sites for the High-Affinity CXCR3 Antagonists NBI-74330 and VUF11211 , 2014, Molecular Pharmacology.

[32]  Maria F. Sassano,et al.  Colloidal Aggregation Causes Inhibition of G Protein-Coupled Receptors , 2013, Journal of medicinal chemistry.

[33]  T. Schwartz,et al.  Activation of the CXCR3 Chemokine Receptor through Anchoring of a Small Molecule Chelator Ligand between TM-III, -IV, and -VI , 2007, Molecular Pharmacology.

[34]  A. Luster,et al.  CXCR3 Requires Tyrosine Sulfation for Ligand Binding and a Second Extracellular Loop Arginine Residue for Ligand-Induced Chemotaxis , 2006, Molecular and Cellular Biology.

[35]  Torsten Schwede,et al.  BIOINFORMATICS Bioinformatics Advance Access published November 12, 2005 The SWISS-MODEL Workspace: A web-based environment for protein structure homology modelling , 2022 .

[36]  Kenneth Jones,et al.  Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. Part 2: Identification of active compounds. , 2008, Bioorganic & medicinal chemistry letters.

[37]  J M Blaney,et al.  A geometric approach to macromolecule-ligand interactions. , 1982, Journal of molecular biology.

[38]  I. D. de Esch,et al.  Identification of novel α7 nicotinic receptor ligands by in silico screening against the crystal structure of a chimeric α7 receptor ligand binding domain , 2012, Bioorganic & medicinal chemistry.

[39]  Kristin E. D. Coan,et al.  Stoichiometry and physical chemistry of promiscuous aggregate-based inhibitors. , 2008, Journal of the American Chemical Society.

[40]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[41]  George A. Kaminski,et al.  Force Field Validation Using Protein Side Chain Prediction , 2002 .

[42]  I. Kuntz,et al.  Ligand solvation in molecular docking , 1999, Proteins.

[43]  B. Honig,et al.  A hierarchical approach to all‐atom protein loop prediction , 2004, Proteins.

[44]  Mette M. Rosenkilde,et al.  Molecular Mechanism of AMD3100 Antagonism in the CXCR4 Receptor , 2004, Journal of Biological Chemistry.

[45]  R. Doms,et al.  CD4-Independent Infection by HIV-2 Is Mediated by Fusin/CXCR4 , 1996, Cell.

[46]  R. Abagyan,et al.  Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists , 2010, Science.

[47]  Peter Kolb,et al.  Structure-based discovery of β2-adrenergic receptor ligands , 2009, Proceedings of the National Academy of Sciences.

[48]  Gerhard Klebe,et al.  A small nonrule of 3 compatible fragment library provides high hit rate of endothiapepsin crystal structures with various fragment chemotypes. , 2011, Journal of medicinal chemistry.

[49]  I. Kuntz,et al.  Automated docking with grid‐based energy evaluation , 1992 .

[50]  W. Hancock,et al.  Requirement of the Chemokine Receptor CXCR3 for Acute Allograft Rejection , 2000, The Journal of experimental medicine.

[51]  J. T. Metz,et al.  Ligand efficiency indices as guideposts for drug discovery. , 2005, Drug discovery today.